Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.70 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.59 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.59 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.59 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.59 |
| ▸ | AKT1 | P31749 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | RECQL | P46063 | 3/20 | 0.52 |
| ▸ | PLIN1 | O60240 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | PLIN5 | Q00G26 | 2/20 | 0.52 |
| ▸ | ABHD5 | Q8WTS1 | 2/20 | 0.52 |
| ▸ | BCHE | P06276 | 1/20 | 0.52 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4929674 | 1.00 | NFE2L2 (0.70) | NFE2L2MEN1KMT2AALDH1A1TDP1 | |
| SCHEMBL3305728 | 0.90 | NFE2L2 (0.64) | NFE2L2MEN1KMT2AALDH1A1TDP1 | |
| SCHEMBL3305717 | 0.90 | NFE2L2 (0.64) | NFE2L2MEN1KMT2AALDH1A1TDP1 | |
| SCHEMBL3305722 | 0.90 | NFE2L2 (0.64) | NFE2L2MEN1KMT2AALDH1A1TDP1 | |
| SCHEMBL464633 | 0.82 | NFE2L2 (1.00) | NFE2L2MEN1KMT2AALDH1A1TDP1 | |
| SCHEMBL6426228 | 0.82 | NFE2L2 (1.00) | NFE2L2MEN1KMT2AALDH1A1TDP1 | |
| SCHEMBL3244802 | 0.82 | NFE2L2 (1.00) | NFE2L2MEN1KMT2AALDH1A1TDP1 | |
| SCHEMBL2232370 | 0.81 | NFE2L2 (0.53) | NFE2L2MEN1KMT2AALDH1A1TDP1 | |
| SCHEMBL3310563 | 0.81 | NFE2L2 (0.53) | NFE2L2MEN1KMT2AALDH1A1TDP1 | |
| SCHEMBL2232374 | 0.81 | NFE2L2 (0.53) | NFE2L2MEN1KMT2AALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040034075-A1 | Sphingosine kinase inhibitors | THE PENNSYLVANIA STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2004-02-19 | — | — | US | claimed |
| US-20080280866-A1 | Method of Treating or Sepsis | HAUSER CARL J | 2008-11-13 | — | — | US | disclosed |
| US-7220764-B2 | Such as 5-(2,4-dihydroxy-benzylidene)-3-(4-methoxy-phenyl)-2-thioxo-thiazolidin-4 -one; for treating/preventing hyperproliferative disease, autoimmune disease, inflammatory disease, or allergy | THE PENNSYLVANIA STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2007-05-22 | — | — | US | disclosed |
| US-7220764-B2 | Such as 5-(2,4-dihydroxy-benzylidene)-3-(4-methoxy-phenyl)-2-thioxo-thiazolidin-4 -one; for treating/preventing hyperproliferative disease, autoimmune disease, inflammatory disease, or allergy | THE PENNSYLVANIA STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2007-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034075-A1 | Sphingosine kinase inhibitors | SPHK1, SPHK2, S1PR1 | NFE2L2 3417/4885MEN1 2072/4885KMT2A 2067/4885 |
| US-20080280866-A1 | Method of Treating or Sepsis | SPHK1, SPHK2, S1PR2 | NFE2L2 1387/4885MEN1 4323/4885KMT2A 4205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.